Notably, levels of IL-6, a central driver of CRS symptoms secondary to chimeric-Ag receptor (CAR)-T or bsTCE treatment,32 were consistently reduced in conditions where type 1 NKT and/or Vγ9Vδ2-T cells were engaged by CD1d-Vδ2 hu-bsTCE. This evidence concerns the gene IL6 and congenital rubella syndrome.